by Stacey Johnson | Feb 10, 2017
There is a trend in the regenerative medicine field to include gene therapies when describing the work being performed by academics and industry, as in “cell and gene therapies.” The wider definition better reflects how the industry is evolving and acknowledges the...
by Nicole Kuchinsky | Feb 8, 2017
In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C>). This was my first...
by Stacey Johnson | Jan 27, 2017
Epidermolysis bullosa (EB) is a rare, and exceedingly painful, skin condition that I’ve written about here and here. Children with EB are sometimes referred to as “butterfly children” because their skin is said to be as fragile as a butterfly’s wings. The severity of...
by Stacey Johnson | Jan 25, 2017
CCRM has been known to hire its graduates, consult with its esteemed professors, review disclosures from its faculty, collaborate on projects, and our Chief Scientific Officer, Dr. Peter Zandstra, is one of its respected professors. All of this to disclose that CCRM...
Comments